Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H14N4O3S |
Molecular Weight | 294.33 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1C=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC1=O
InChI
InChIKey=SIBQAECNSSQUOD-UHFFFAOYSA-N
InChI=1S/C12H14N4O3S/c1-2-16-8-7-11(14-12(16)17)15-20(18,19)10-5-3-9(13)4-6-10/h3-8H,2,13H2,1H3,(H,14,15,17)
Molecular Formula | C12H14N4O3S |
Molecular Weight | 294.33 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/769287
Sources: https://www.ncbi.nlm.nih.gov/pubmed/769287
Sulfacytine is a short-acting sulfonamide, which was used for the treatment uncomplicated urinary tract infections, but was discontinued. This drug is a is a competitive inhibitor of the dihydropteroate synthetase, that inhibits bacterial synthesis of dihydrofolic acid by preventing the condensation of the peridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2013 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1195474 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | RENOQUID Approved UseUnknown Launch Date1975 |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3606051/ |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
SULFACYTINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3606051/ |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
SULFACYTINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/769287
1Gm per day
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:45:46 GMT 2023
by
admin
on
Sat Dec 16 17:45:46 GMT 2023
|
Record UNII |
T795873AJP
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29739
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2891
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
78902
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | RxNorm | ||
|
100000083262
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
DTXSID6023606
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201056
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
Sulfacytine
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
C47734
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
T795873AJP
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
5322
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
1401-49-6
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
NO STRUCTURE GIVEN | |||
|
2499
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
m10304
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | Merck Index | ||
|
356717
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
3272
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
SUB10690MIG
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
17784-12-2
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
C100141
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY | |||
|
DB01298
Created by
admin on Sat Dec 16 17:45:46 GMT 2023 , Edited by admin on Sat Dec 16 17:45:46 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |